In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Personalized Medicine: A Trip Down Memory Lane

Executive Summary

Free article: What In Vivo has been saying about personalized medicine in this century.

The phrase "personalized medicine" first appeared in In Vivo in January 2001 in an article entitled "Millennium Predictive's Outcome." In that story we examined Millennium Pharmaceuticals' deal with Roche Diagnostics to develop prognostics and therapeutics for rheumatoid arthritis. We found it notable that it was the second deal involving delivery of targets to a large diagnostics company (Millennium's 1999 tie-up with Becton Dickinson was first), but we were more intrigued that Millennium had opted to reabsorb two-thirds of the programs from its Millennium Predictive Medicine subsidiary, setting the stage for the parent company's "major, web-based personalized medical information play" by the end of 2001.

It didn't work out.

Since then, our coverage of personalized medicine has kept pace with business developments in this rapidly growing field, culminating in our March 2017 issue exclusively devoted to the topic. Behind the oft-repeated mantra – right drug, right dose, right patient, right time – lie many complexities. We explore some of them this month: how to achieve true patient-centricity in personalized medicine, the expansion of companion diagnostics beyond oncology, the role of data analytics in accelerating the development of targeted therapies, and hard evidence that the use of biomarkers does have a positive impact on clinical trial success.

Below, a look at In Vivo's key articles on personalized medicine from 2001-2016.

A Look Back...

Our March focus on personalized medicine is the first of four themed issues that we are planning in 2017. Next up, an in-depth look at Oncology in May, followed by Dealmaking in September and Market Access in November. We'd love to hear your thoughts on what we should cover those months, or other topics you'd like us to address in 2017. Email me at Nancy.Dvorin@Informa.com.

Advertisement

Related Content

Personalized Medicine: A Patient Primer On Best Practice
One Size No Longer Fits All: The Personalized Medicine Trial Landscape
Companion Diagnostics: The Expanding Reach Of Personalized Medicine
Flatiron Aims To Accelerate, Personalize Cancer Research

Topics

Advertisement
UsernamePublicRestriction

Register

IV005058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel